New Elite Feature: Chart Templates — Your indicators and design everywhere on Finviz

ZENTALIS PHARMACEUTICALS

Contributing Author

Recent Articles by ZENTALIS PHARMACEUTICALS

Mar-26	Zentalis Pharmaceuticals Reports Full Year 2025 Financial Results and Operational Updates ZNTL -21.35% ZNTL GlobeNewswire
Mar-17	Zentalis Pharmaceuticals to Present Two Posters at the American Association for Cancer Research (AACR) Annual Meeting 2026 ZNTL -7.88% ZNTL GlobeNewswire
Feb-18	Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences ZNTL GlobeNewswire
Feb-03	Zentalis Pharmaceuticals to Participate in Upcoming Investor Conference ZNTL +12.35% ZNTL -9.57% GlobeNewswire
Jan-06	Zentalis Pharmaceuticals Provides Corporate Update and Highlights Key Milestones and Expected Momentum in the Azenosertib Development Program for 2026 ZNTL +29.93% GlobeNewswire
Nov-10	Zentalis Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Progress ZNTL +6.06% ZNTL GlobeNewswire
Nov-03	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ZNTL -8.33% ZNTL GlobeNewswire
Nov-03	Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences ZNTL GlobeNewswire
Oct-13	Zentalis Pharmaceuticals Announces Four Azenosertib Posters Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics ZNTL GlobeNewswire
Oct-01	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ZNTL +7.79% ZNTL GlobeNewswire
Sep-02	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ZNTL GlobeNewswire
Aug-28	Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences ZNTL GlobeNewswire
Aug-26	Zentalis Pharmaceuticals Appoints James B. Bucher, JD, as Chief Legal Officer and Corporate Secretary ZNTL GlobeNewswire
Aug-06	Zentalis Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Progress ZNTL +5.07% ZNTL GlobeNewswire
Jul-01	Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) ZNTL GlobeNewswire
Jun-02	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ZNTL +6.25% ZNTL +5.79% GlobeNewswire
May-14	Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress ZNTL +5.88% ZNTL GlobeNewswire
May-01	Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) ZNTL GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)